Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
ARESTIN®
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Raxone®/Catena® (idebenone)
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Architecture of human mTOR complex 1.
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.

Pages